Advertisement

Topics

Search Results for "Rituximab Patent"

08:47 EST 11th December 2016 | BioPortfolio

Matching Channels

CD20 Antibodies

The chimeric anti-CD20 antibody rituximab (Rituxan & MabThera) from Biogen Idec and Genentech/Roche is one of the world’s commercially most successful antibodies (2007 sales of over US$ 5 bl...

Biosuperior Antibodies

After biosimilar versions of therapeutic proteins have become reality in Europe and in the US, now it’s the turn of therapeutic antibodies to be in the line of fire. Patents of the first wave of...

India

India, in the Asian subcontinent is the world’s fourth largest producer of pharmaceuticals, and is thought as one of the most promising biotech markets in the world. Several important steps ...

Tumor Necrosis Factor TNF Products

Tumor Necrosis Factor (TNF) and TNF receptor antagonists and agonists used to treat TNF-mediated inflammatory diseases such as rheumatoid arthritis or to treat cancer. TNF blockers are the commerc...

Matching News

Combating Rituximab-Induced Side Effects

I currently have a 77-year-old non-Hodgkin lymphoma patient that recently started bendamustine (Treanda)/rituximab combination therapy. After increasing the intravenous (IV) rituximab rate per protoco...

Rituximab induces phenotypical and functional changes of NK cells in a non-malignant experimental setting

Rituximab has broad and increasing application in rheumatic diseases. It is known from lymphoma studies that natural killer (NK) cells can lyse rituximab-coated transformed B cells. However, the role ...

Rituximab biosimilar shows pharmacokinetic bioequivalence in patients with RA

GP2013, a proposed rituximab biosimilar, demonstrated pharmacokinetic bioequivalence to rituximab in patients with rheumatoid arthritis, according to results presented at the EULAR Annual Congress.Res...

Positive phase III results for Celltrion’s rituximab biosimilar

Phase III studies of a rituximab biosimilar from Celltrion have, according to the company, shown that the biosimilar is ‘equivalent’ to Roche’s MabThera/Rituxan (rituximab).

B-cell imaging with zirconium-89 labelled rituximab PET-CT at baseline is associated with therapeutic response 24 weeks after initiation of rituximab treatment in rheumatoid arthritis patients

B cells are key players in the pathogenesis of rheumatoid arthritis (RA). Although successful in 50–60% of patients with RA, anti-B-cell therapy given as rituximab could be more efficient by identif...

Rituximab for Thrombotic Thrombocytopenic Purpura

Adding rituximab to plasma exchange and steroids improved relapse-free survival in a nonrandomized trial.

ECTRIMS: Rituximab Beats MS Drugs in Swedish Registry Study (CME/CE)

(MedPage Today) -- Finds survival advantage for rituximab over fingolimod and natalizumab

Rituximab Improves Outcomes in Adult Acute Lymphoblastic Leukemia

Adding rituximab to ALL chemotherapy improved event-free survival in patients with CD20-positive, Ph-negative ALL.

Matching PubMed Articles

Time Savings with Rituximab Subcutaneous Injection versus Rituximab Intravenous Infusion: A Time and Motion Study in Eight Countries.

Rituximab is a standard treatment for non-Hodgkin lymphoma. The SABRINA trial (NCT01200758) showed that a subcutaneous (SC) rituximab formulation did not compromise efficacy or safety compared with in...

Patent highlights June-July 2016.

A snapshot of noteworthy recent developments in the patent literature of relevance to pharmaceutical and medical research and development.

Searching bioremediation patents through Cooperative Patent Classification (CPC).

Patent classification systems have traditionally evolved independently at each patent jurisdiction to classify patents handled by their examiners to be able to search previous patents while dealing wi...

Is rituximab sub-optimally dosed in indolent B cell lymphoma?

Rituximab pharmacokinetics are affected by gender, age and weight and can affect outcomes in aggressive B cell lymphoma. Less is known about the pharmacokinetics of rituximab in indolent B cell lympho...

Rituximab-induced lung disease.

Pulmonary toxicity is a rare complication of Rituximab therapy. Although Rituximab is relatively safe and can be administered in an outpatient setting, Rituximab-associated lung disease has been repor...

Search Whole site using Google

Loading
Quick Search
Advertisement
 
Advertisement Advertisement